Claro Advisors LLC Increases Stake in Cencora, Inc. (NYSE:COR)

Claro Advisors LLC increased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 851.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,888 shares of the company's stock after buying an additional 10,638 shares during the quarter. Claro Advisors LLC's holdings in Cencora were worth $2,676,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of COR. Fisher Asset Management LLC acquired a new position in Cencora in the 4th quarter worth approximately $244,000. First Hawaiian Bank acquired a new stake in shares of Cencora during the 1st quarter worth approximately $1,621,000. Rise Advisors LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $25,000. Massmutual Trust Co. FSB ADV acquired a new stake in shares of Cencora during the 1st quarter worth approximately $235,000. Finally, Alaska Permanent Fund Corp acquired a new stake in shares of Cencora during the 1st quarter worth approximately $1,819,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on COR shares. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Wells Fargo & Company raised their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 1st. Evercore ISI dropped their price target on shares of Cencora from $270.00 to $250.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Robert W. Baird dropped their price target on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating on the stock in a research note on Friday, September 6th. Finally, Bank of America reissued a "neutral" rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $259.44.

Insiders Place Their Bets

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now directly owns 19,980,000 shares of the company's stock, valued at $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Silvana Battaglia sold 1,473 shares of the business's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares of the company's stock, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.80% of the stock is owned by insiders.

Cencora Price Performance

COR traded up $1.79 on Friday, reaching $237.43. 1,203,109 shares of the company's stock were exchanged, compared to its average volume of 1,423,747. The stock has a market cap of $47.36 billion, a PE ratio of 25.78, a P/E/G ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a twelve month low of $182.75 and a twelve month high of $247.66. The stock's fifty day moving average price is $232.39 and its 200-day moving average price is $231.18. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. Cencora's quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.92 earnings per share. Sell-side analysts expect that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were paid a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend was Friday, August 9th. Cencora's dividend payout ratio (DPR) is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.